pharm edaily

[Kim Jinsoo, Edaily Reporter] Celltrion announced on July 29 that it has been selected as the preferred negotiation partner for the acquisition of a U.S.-based company that owns an active pharmaceutical ingredient (API) manufacturing facility. The company has signed an exclusive negotiation agreement, though the name of the target firm has not been disclosed.

(Celltrion)

Celltrion has been reviewing the acquisition of a U.S.-based API manufacturer to address tariff risks on pharmaceutical exports to the U.S. and to build a local production system that enhances cost competitiveness.

The company said it will conduct a due diligence review of the U.S. facility owned by the acquisition target and will decide whether to proceed with a final agreement based on the results.

Through the investment, Celltrion aims to expand production capacity, improve cost efficiency, generate immediate revenue by using the facility for contract manufacturing of existing products, and strengthen local R&D capabilities to maximize synergies with advanced technologies.

Celltrion stated it will disclose further details once a definitive agreement is signed.